Antibiotic resistance increases the cost of treating a bacterial infection by $1,383 and adds $2.2 billion to the country’s health care spending. Inpatient care is the biggest contributor to the incremental cost. Also costs related to antibiotic resistance were higher for older people and those in poor health.
Clinical benefits associated with new cancer therapies do not justify the high prices for the medications, and some value-based payment system is needed, according to a study published in the Journal of Oncology Practice. That’s especially true regarding incremental costs, the difference in total drug price between the novel medications and standard treatment.